Clinical Results of Perftoran Application: Present and Future

Figures & data

Table 1 Perftoran composition and its physical-chemical properties

F-decalin and its satellites	7.0 ml
F—N-(4-methylcyclohexyl)-piperidine and its satellites	3.0 ml
Proxanol-268	4.0 g
NaCl	0.6 g
KCl	0.039 g
MgCl2	0.019 g
NaHCO3	0.065 g
NaH2PO4	0.02 g
Glucose	0.2 g
H2O	to 100 ml
[F^−]	10 µM
Osmotic pressure	300 mOsM
pH	7.3
Viscosity	2.3 cP

Table 2 Distribution of patients according to indications during clinical trials

Indications	Doses, ml per kg BW	Summary doses, L	Patients distributions	% side reactions
1. Acute blood loss and hemorrhagic shock	6–30	1.0–5.0	23.5%	2%
2. Polytrauma, cranial-cerebral trauma, shock	4–12	0.4–1.2	20%	0%
3. Toxic-infection shock	4–8	0.4–1.0	12,7%	0%
4. Occlusion of blood vessels and acute heart infarct	4–6	0.4–0.8	20,7%	20%
5. Cardioplegia	–	1.0–2.0	11.1%	0%
6. Transplantation	30	1.0–2.0	4,8%	0%
7. Burns, oncology & others	2–8	0.1–1.0	8.2%	25%
Total 912 patients			100%	6,9%

Table 3 Indications and distribution of patients treated with Perftoran in comparative studies listed in Russia scientific literature for the period up to 2002

Indications	Total 3332/Perftoran treated 1823	Distribution of patients with Perftoran
1. Blood losses, multiple organ failure	862/401	22.0%
2. Disorders of perfusion and microcirculation (without blood loss)	490/292	16.02
3. Dysfunction of inflammatory response	269/163	8.9%
4. Detoxication	375/170	9.3%
5. Lung function damage, RDSA	197/152	8.3%
6. Cranial-cerebral trauma	184/134	7.3%
7. Burns, thermal shock	123/53	2.9%
8. Transplantation	206/87	4.8%
9. Cardioplegia, cardiopulmonary bypass	165/72	3.9%
10. Local application: wound & ulcer of mucous, skin, spinal cord	461/299	16.2%

Table 4 The place of perftoran in infusion-transfusion therapy of blood losses

Blood loss volume		Transfusion means and doses (ml)
ml	% Circulat. Blood Volume	Crystalloids	Perftoran	Colloids	Albumin 10%	Fresh frozen plasma	Red blood cells & platelets
<750	<15	1500	200–300	–	–	–	–
750–1500	15–30	1500–2000	500–700	600–800	–	–	–
1500–2000	30–40	1000–1500	800–1000	800–1200	100–200	1000–1500	on indications
>2000	>40	800–1000	1000–1500	1200–1500	200–300	1500–2000	2–6 units

Table 5 Results of Perftoran treatment at the occlusive vessels diseases of legs (Rehabilitation Center of Government Medical Department, 1999–2002)

Quantity & average age of patients	Treatment	Painfree distances, m (% of patients)			Pains at rest	Stages of diseases
	before Perftoran	∼180 (100%)			50%	2–3b
N = 92	Perftoran 200 ml × 2–3 every 6–9 months	1200	750	200	0	1–2a
68 years		(87%)	(9%)	(4%)